Our Pricing

Best Weight Loss Injections Reviews - Lowest Price UK

Published on: June 03, 2026

Searching for the best weight loss injections reviews UK with transparent pricing? At Cured Pharmacy, we offer UK-licensed weight loss injections including Mounjaro, Wegovy, and Saxenda, all dispensed following a free clinical consultation with our UK-registered prescribers. Our patients benefit from guaranteed lowest prices, genuine medications, and completely discreet packaging delivered directly to your door.

How GLP-1 Weight Loss Injections Work

GLP-1 receptor agonists are a class of injectable medications that mimic naturally occurring hormones in your body to regulate appetite and blood sugar levels [1]. These medications work by slowing gastric emptying, reducing hunger signals to the brain, and improving insulin sensitivity, creating a multi-pathway approach to sustainable weight management.

Clinical trials have demonstrated that GLP-1 treatments can produce significantly greater weight loss compared to lifestyle interventions alone. In the STEP 1 trial, participants using semaglutide achieved an average 14.9% body weight reduction over 68 weeks, whilst the SURMOUNT-1 trial showed tirzepatide users lost up to 22.5% of their initial body weight [1][2]. These results represent some of the most substantial weight reductions ever recorded in pharmaceutical obesity treatment.

The MHRA has licensed several GLP-1 medications for weight management in the UK, each with distinct pharmacological profiles. Your response to treatment depends on multiple factors including your baseline BMI, metabolic health, adherence to prescribed dosing schedules, and concurrent lifestyle modifications. All prescription weight loss injections available through Cured Pharmacy require clinical assessment by a UK prescriber to ensure suitability and safety.

Mounjaro (Tirzepatide): Dual-Action Weight Loss Treatment

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for chronic weight management [2]. Unlike single-pathway GLP-1 medications, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, producing enhanced metabolic effects and superior weight loss outcomes in head-to-head clinical comparisons.

The SURPASS clinical trial programme demonstrated tirzepatide's exceptional efficacy across multiple dosing strengths. In SURPASS-2, participants on the 15mg maintenance dose achieved an average 12.4kg weight reduction compared to 6.2kg with semaglutide 1mg over 40 weeks [2]. The medication is administered once weekly via a pre-filled KwikPen injector, with dosing gradually titrated from 2.5mg to a maximum of 15mg based on individual tolerance and response.

At Cured Pharmacy, Mounjaro is available from £135.00, representing the lowest guaranteed price for genuine UK-licensed tirzepatide in the country. Your treatment begins with a free online consultation completed in under three minutes, reviewed by our UK-registered clinical team including superintendent pharmacist Tarun Kumar (GPhC 2233073). Subject to prescriber approval, your medication is dispensed from our GPhC-registered pharmacy (9012511) and delivered in completely discreet packaging.

Who Can Use Mounjaro?

Mounjaro is licensed for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia [2]. Your UK prescriber will assess your full medical history, current medications, and contraindications during the consultation process. Common exclusions include pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2.

Wegovy (Semaglutide): Proven Weight Loss Results

Wegovy contains semaglutide, a GLP-1 receptor agonist extensively studied in the STEP clinical trial programme involving over 4,500 participants [1]. The medication works by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve glycaemic control, creating sustainable conditions for significant weight reduction when combined with dietary and exercise modifications.

In the landmark STEP 1 trial, participants receiving semaglutide 2.4mg weekly achieved an average 14.9% reduction in body weight over 68 weeks, compared to 2.4% with placebo [1]. Notably, 86% of semaglutide users achieved at least 5% weight loss, whilst 69% reached the clinically significant threshold of 10% or greater reduction. These results established semaglutide as one of the most effective pharmaceutical interventions for obesity management.

Wegovy is administered once weekly via a pre-filled FlexTouch pen, with dosing escalated gradually from 0.25mg to the maintenance dose of 2.4mg over 16 weeks. This titration schedule minimises gastrointestinal side effects whilst allowing your body to adapt to the medication's metabolic effects. Treatment requires ongoing clinical supervision, and your UK prescriber will monitor your progress and adjust dosing as clinically appropriate.

Wegovy Dosing Schedule

The standard Wegovy titration follows a structured 16-week escalation: 0.25mg weekly for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then maintenance at 2.4mg weekly [1]. This gradual increase significantly reduces the incidence of nausea and gastrointestinal discomfort reported in clinical trials. Your prescriber may adjust this schedule based on your individual tolerance and clinical response.

Comparing Weight Loss Injections: Clinical Evidence

Direct comparison trials provide valuable insights into relative efficacy between different GLP-1 medications. The SURPASS-2 head-to-head study compared tirzepatide against semaglutide 1mg in participants with type 2 diabetes, demonstrating superior weight loss with all tirzepatide doses [2]. At 40 weeks, the 15mg tirzepatide group achieved 12.4kg average reduction versus 6.2kg with semaglutide, representing nearly double the weight loss outcome.

However, medication selection involves more than efficacy data alone. Tolerability profiles differ between agents, with tirzepatide showing higher rates of gastrointestinal side effects in some trials but also greater discontinuation rates with semaglutide in others [1][2]. Individual patient factors including injection frequency preference, previous GLP-1 exposure, comorbid conditions, and cost considerations all influence the optimal choice.

Your UK prescriber at Cured Pharmacy will evaluate your complete medical profile, weight loss goals, and treatment preferences during your consultation. Both tirzepatide and semaglutide require commitment to concurrent lifestyle modifications for optimal results. Clinical guidelines emphasise that these medications are adjuncts to, not replacements for, reduced-calorie diets and increased physical activity [3].

Saxenda (Liraglutide): Daily Injection Alternative

Saxenda contains liraglutide, an earlier-generation GLP-1 receptor agonist administered via daily subcutaneous injection [4]. Whilst newer weekly formulations have largely superseded daily options, liraglutide remains a valuable alternative for patients who prefer more frequent dosing or have contraindications to longer-acting GLP-1 medications.

The SCALE clinical programme demonstrated liraglutide 3mg daily produced an average 8% body weight reduction over 56 weeks, with 63.2% of participants achieving at least 5% weight loss [4]. These outcomes, whilst more modest than those observed with tirzepatide or high-dose semaglutide, still represent clinically meaningful improvements in metabolic health markers including HbA1c, blood pressure, and lipid profiles.

Saxenda is titrated from 0.6mg daily up to the maintenance dose of 3mg over five weeks, allowing gradual adaptation to the medication's effects. The daily injection schedule requires greater treatment adherence compared to weekly alternatives, but some patients report better appetite control with the more frequent dosing pattern. Your prescriber will discuss whether daily or weekly administration better suits your lifestyle and treatment goals.

Saxenda vs Weekly Injections

The primary distinction between Saxenda and newer GLP-1 medications lies in administration frequency and magnitude of weight loss. Whilst Saxenda requires daily injections and typically produces 8-9% average weight reduction, weekly options like Wegovy and Mounjaro deliver 15-22% reductions with once-weekly dosing [1][2][4]. However, individual responses vary considerably, and some patients achieve excellent results with liraglutide whilst experiencing intolerable side effects with longer-acting formulations.

Oral Weight Loss Medications: Orlistat and Alternatives

For patients who prefer non-injectable options, oral weight loss medications provide an alternative approach to pharmaceutical weight management. Orlistat, available as prescription-strength 120mg (Xenical) or over-the-counter 60mg formulations (Alli, Orlos), works through a completely different mechanism than GLP-1 injections by inhibiting pancreatic lipase enzymes that digest dietary fats [5].

Clinical trials demonstrate orlistat 120mg three times daily produces an average 2.9kg greater weight loss compared to placebo over one year when combined with a reduced-calorie diet [5]. Whilst these results are more modest than injectable GLP-1 medications, orlistat offers advantages including oral administration, no injection-related side effects, and suitability for patients with contraindications to incretin-based therapies.

The primary tolerability consideration with orlistat involves gastrointestinal effects related to its mechanism of action. Undigested fats passing through the digestive system can cause oily stools, flatulence, and faecal urgency, particularly when consuming high-fat meals [5]. These effects are manageable through dietary fat restriction and typically diminish as patients adapt their eating patterns. Your prescriber will assess whether orlistat's risk-benefit profile suits your individual circumstances and weight loss objectives.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (Clinical guideline CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to prescribed treatment, dietary modifications, and physical activity levels.